Literature DB >> 7601426

Inhibition of gallbladder emptying decreases cholesterol saturation in bile in the Richardson ground squirrel.

J G Pauletzki1, Q W Xu, E A Shaffer.   

Abstract

Impaired gallbladder emptying is frequent in cholesterol gallstone disease as well as in predisposing conditions like pregnancy and obesity. Gallbladder hypomotility is considered a pathogenic factor for gallstone formation, providing the residence time for cholesterol crystal nucleation, but any effect on the enterohepatic circulation of bile acids and subsequently on biliary lipid composition is unknown. Therefore, we studied the effect of prolonged suppression of gallbladder emptying with a cholecystokinin (CCK-A) receptor antagonist on bile formation in Richardson ground squirrels fed a trace versus a 1% cholesterol diet. Biliary lipid secretion was measured directly and bile acid pool size assessed by isotope dilution ([14C]-cholic acid). Gallbladder contraction was determined in vitro in response to CCK. The CCK-antagonist (MK-329) greatly inhibited gallbladder contraction in vitro and increased gallbladder fasting volume and bile acid pool size in vivo. It significantly lowered the cholesterol saturation index by 35% and 46% in hepatic bile and by 18% and 28% in gallbladder bile in the trace and cholesterol diet groups, respectively. Bile acid secretion and bile flow doubled with the CCK-receptor antagonist. Chronic CCK receptor antagonist-induced inhibition of gallbladder emptying increases bile acid secretion and thereby decreases cholesterol saturation in bile. Extensive biliary hypomotility thus leads to a more rapid cycling of bile acids by depriving the gallbladder of its function in the enterohepatic circulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7601426

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis.

Authors:  Sandeep Nadella; Victor Ciofoaia; Hong Cao; Bhaskar Kallakury; Robin D Tucker; Jill P Smith
Journal:  Dig Dis Sci       Date:  2019-10-09       Impact factor: 3.199

Review 2.  Smooth muscle function and dysfunction in gallbladder disease.

Authors:  Piero Portincasa; Agostino Di Ciaula; Gerard P vanBerge-Henegouwen
Journal:  Curr Gastroenterol Rep       Date:  2004-04

3.  Association of caveolin-3 and cholecystokinin A receptor with cholesterol gallstone disease in mice.

Authors:  Guo-Qiang Xu; Cheng-Fu Xu; Hong-Tan Chen; Shan Liu; Xiao-Dong Teng; Gen-Yun Xu; Chao-Hui Yu
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

4.  Effects of tegaserod on bile composition and hepatic secretion in Richardson ground squirrels on an enriched cholesterol diet.

Authors:  Ronald Mathison; Eldon Shaffer; Hans-Juergen Pfannkuche; David Earnest
Journal:  Lipids Health Dis       Date:  2006-06-22       Impact factor: 3.876

5.  Gallbladder motility change in late pregnancy and after delivery.

Authors:  J S Hahm; J Y Park; S C Song; Y J Cho; K H Moon; Y H Song; O Y Lee; H S Choi; B C Yoon; M H Lee; C S Kee; K N Park
Journal:  Korean J Intern Med       Date:  1997-01       Impact factor: 2.884

6.  A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.

Authors:  Robin D Tucker; Victor Ciofoaia; Sandeep Nadella; Martha D Gay; Hong Cao; Matthew Huber; Anita Safronenka; Narayan Shivapurkar; Bhaskar Kallakury; Annie J Kruger; Alexander H K Kroemer; Jill P Smith
Journal:  Dig Dis Sci       Date:  2019-07-11       Impact factor: 3.199

7.  A computer study of the risk of cholesterol gallstone associated with obesity and normal weight.

Authors:  Krystian Kubica; Joanna Balbus
Journal:  Sci Rep       Date:  2021-04-23       Impact factor: 4.379

8.  Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment.

Authors:  Christine C Hsu; Sunil Bansal; Hong Cao; Coleman I Smith; Aiwu Ruth He; Martha D Gay; Yaoxiang Li; Amrita Cheema; Jill P Smith
Journal:  Pharmaceutics       Date:  2022-03-12       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.